ストックスクリーナーアプリを入手
1.80
5.76%
-0.11
Akebia Therapeutics Inc (AKBA) 最新ニュース
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Declines By 19.7% - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Upgraded to Hold at StockNews.com - MarketBeat
Akebia Therapeutics extends loan agreement, receives $9.3M - MSN
Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline - Seeking Alpha
Akebia Therapeutics, Inc. (NASDAQ:AKBA) CEO John P. Butler Sells 144,250 Shares - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Insider Sells $116,804.10 in Stock - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) SVP Sells $106,062.60 in Stock - MarketBeat
Insider Selling: Akebia Therapeutics, Inc. (NASDAQ:AKBA) CAO Sells 30,202 Shares of Stock - MarketBeat
Akebia Therapeutics extends loan agreement, receives $9.3M By Investing.com - Investing.com Canada
$10.7 Billion Healthcare Mobile Robots Market Outlook, 2030 - GlobeNewswire
$10.7 Billion Healthcare Mobile Robots Market Outlook, 2030 by Type, End Use and RegionAkebia Therapeutics, ABB, Aethon, Omron Corp., and Amazon Lead the Competition - Yahoo Finance
Akebia Therapeutics' chief accounting officer sells $63,424 in stock - MSN
Akebia Therapeutics' chief commercial officer sells $116,804 in stock - MSN
Akebia therapeutics' chief medical officer sells $106,062 in stock By Investing.com - Investing.com South Africa
Akebia therapeutics' chief medical officer sells $106,062 in stock - MSN
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics CEO John Butler sells $302,925 in stock By Investing.com - Investing.com Canada
Akebia Therapeutics' chief commercial officer sells $116,804 in stock By Investing.com - Investing.com South Africa
Akebia's Latest Talent Investment: Strategic Options Grant Details Revealed - StockTitan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Significant Increase in Short Interest - MarketBeat
Akebia Therapeutics CEO John Butler sells $302,925 in stock - MSN
SEC Form S-8 filed by Akebia Therapeutics Inc. - Quantisnow
Akebia Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Akebia Therapeutics (NASDAQ:AKBA) Trading 10.9% HigherTime to Buy? - MarketBeat
H.C. Wainwright maintains Akebia stock Buy rating, $7.50 target - MSN
Akebia Therapeutics (NASDAQ:AKBA) Trading Down 4.4%What's Next? - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified - Simply Wall St
Better Luck Next Year: US FDA CRLs May Be Rising, But Are Not The End Of The Story - News & Insights
Akebia Therapeutics (NASDAQ:AKBA) Trading Up 10.9%Here's What Happened - MarketBeat
Lobbying Update: $240,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Bought by Barclays PLC - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com
What is HC Wainwright's Forecast for AKBA FY2024 Earnings? - MarketBeat
Equities Analysts Issue Forecasts for AKBA FY2024 Earnings - Defense World
FY2024 Earnings Forecast for AKBA Issued By HC Wainwright - MarketBeat
Analysts Offer Predictions for AKBA FY2029 Earnings - MarketBeat
Brokers Issue Forecasts for AKBA FY2029 Earnings - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from HC Wainwright - Defense World
Akebia Therapeutics (NASDAQ:AKBA) Rating Lowered to Sell at StockNews.com - MarketBeat
3.23%
3.94%
大文字化:
|
ボリューム (24 時間):